The current practice o f patient-controlled analgesia has grown from empirical observations. Although several variants ofpatient-controlled analgesia, bolus doses, infirsions, or combinations of both, have been strggested, a scientific basis for advocating one variant over the ofhers has been lacking. Most systems have been based on the simplest system, boltrs demand, although the use of a combined bolus and background infusion method has theoretical merit. Sirnilarl.~, a scientific basis .for setting s he variables of patient-controlled analgesia, drug choice, incremental dose, rnaxirntrrn dose and lockozrt interval, also has been lacking. Settings for these variables may be rafionalised post hoc on the basis of the physicnc~lic~inical properties and global pharmacokinetic properties of the opioids used but knowledge oj'these properties has not helped in setting the variables a priori. Foremost, the drug choice should be based on therapezr/ic index. Knowledge of the regional kinetics of drug (influx and efJux)from brain may provide a more logical basis for setting the patient-confrolled analgesia variables but such information can on1.v come from animal experiments. More research is required if patient-controlled analgesia is to become anything but an empirical tool in the quest for improved analgesia in patients.
In some areas of medicine, improved pharmacotherapy is more likely to come from attention to methods of drug delivery than from efforts to design new drugs, e.g. those in which it is recognised that there is appreciable variability in the clinical needs of the patients or in the responses of patients to the drugs used.
In considering possible ways of improving the drug treatment of acute pain, Norman' suggested that these questions first should be asked about the system to be used to deliver analgesia:
(1) who selects the drug to be used? (2) 'who decides the dose? (3) who decides when the drug should be given? (4) who decides w.hen more drug is necessary? (5) who assesses the efficacy ofthe treatment? (6) who assesses the dangers?
In most instances, the doctor selects the drug from a range approved by the appropriate authorities and then decides the dose and times for remedication; the nurse may decide when the first dose is necessary and usually decides when subsequent doses are necessary. Deciding who is to assess the efficacy of the regimen, however, is more difficult. The nurse can only administer drug that has been ordered by the doctor. On the basis of perceived dangers (or lack of knowledge), inefficacious dosage regimens are frequently ordered and/or administered. 2 Therefore, in answer to the question 'who is in control of the drug delivery system?', Norman l proposed that the logical choice was the patient -not the medical or nursing staff. Such patient-controlled analgesia (PCA) methods appear to have been remarkably successful. 3
Patient-controlled analgesia: the variants and the variables
There are four basic variants of PCA: Bolus demand: demands of a fixed bolus dose are made to a fixed maximum amount and fixed maximum rate; this is the most commonly used system. Infusion demand: demands are administered as an infusion; Norman 1 reported that this method has not yet been studied. Bolus demand and constant infusion: demand bolus doses supplement a background infusion; this is a commonly used system. Bolus demand and variable infusion: a delivery system-based microprocessor monitors the demand rate and adapts the background infusion accordingly; this is a research-oriented system and the algorithm to determine the infusion rate has not been tested in practice. The background to each of these variants has been described elsewhere. 1.3 There are also four basic variables within a PCA system: the drug choice, the incremental dose per demand, the maximum dose (or dose rate), and the lockout interval between demands. These also have been introduced and discussed from a clinical viewpoint;3 however, the scientific basis of PCA has not been systematically examined in other reports.
If the dosage regimen is to be placed in the hands of the patient, what then is the state of the science relating to the choice of system variant and the setting of the variables of the chosen system? It will be seen from this review that it is not at all well-advanced despite the volumes written about the pharmacokinetics and effects of analgesics agents.
The pharmacokinetic design of dosage regimens
Attempts to improve opioid dosage regimens have been based on the pharmacokinetic and pharmacodynamic characteristics of the drugs to be used where these were known. 2-6 It has been proposed that there is a continuous relationship between opioid agonist blood concentrations and response, that there is a minimum blood drug concentration associated with effective analgesia (MEAC) and that pharmacokinetic techniques can be applied to design dosage regimens to achieve the target" blood drug concentrations. 5 ,6 However, it has been pointed out that the limitations of 'pharmacokinetically designed' dosage regimens of analgesics are largely related to unpredictable variability in both the doseblood concentration and the blood concentration-effect relationships.3 The rational treatment of pain with all of its attendant physical, biochemical, physiological, psychological and sociological variables may have a different basis to other forms of drug treatment and thus predetermined individualisation of dosage is extremely difficult.
Opioid administration is intended to achieve a minimum effective (analgesic) concentration of the drug in blood (MEAC) without producing side effects. Since this MEAC varies greatly between patients, its achievement and maintenance should be guided more by individual titration to response than by recipes based upon published pharmacokinetics. At the present state of knowledge, these reflect drug blood concentrations in samples of populations 7 without necessarily being able to reflect drug effects in the individual patients being treated. Unfortunately the MEAC determined under specific conditions is not necessarily constant and may, for example, be increased by movement 'or physiotherapy, or decreased by distraction. Its value as usually reported is the mean MEAC calculated from a series of MEACs measured at discrete times (MEACt). There are several factors which need to be controlled if the drug concentration is to accurately represent the MEAC. 21 An individual value of ME ACt may differ by 30% from the (mean) MEAC 21 and which may systematically change by 5-11 % per hour. 8 The coefficients of variation in MEAC between patients have been reported to range from Anaesthesia and Imensil'e Care, rof. 16 . No. 4. 1\'00 'ember. 1988 39% to 57% after intra-abdominal surgery. 8.9 In the context of pain control by PCA, it is not important whether or not a MEAC really exists. 11 If a MEAC does exist, then PCA ought to be capable of characterising it, even if it shows time-dependence due, for example, to diminishing stimulus or to tolerance. Ifit does not exist, PCA still provides a way of treating the vagaries of the patients' needs for analgesic medication.
Physicochemical properties of opioids: determinants of drug choice and dose
The incremental dose of any drug chosen for PCA depends on the potency of the chosen drug. In a systematic comparison of the different drugs, the physicochemical properties are a logical starting point. All of the currently used pure opioid agonists are basic amines and, except for morphine, are lipophilic molecules; morphine is more hydrophilic. It is generally believed that the unbound, non-ionised form of the drug is free to cross membranes in the body and that this is done at rates which parallel the lipid solubilities of the agents. The background and relevance of this line of reasoning have been discussed previously (e.g. see Reference 4), although data are emerging for other drugs with similar chemistry that question the validity of this traditional teaching. 12 . 13 On the basis of lipid solubility, the rates of CNS penetration will decrease in the order of fentanyl and its congeners (sufentanil, alfentanil) > methadone > pethidine > morphine. On the basis of fraction unionised, the order is alfentanil > pethidine > sufentanil and fentanyl > methadone and morphine. On the basis of unbound fraction, the order is morphine > pethidine > methadone and the fentanyls. However, these considerations also apply to other regions of the body that 'take up' drug without producing analgesia so that the fraction of dose reaching the receptors cannot be easily determined. The fact that it is difficult to discern marked differences in the rate of onset of analgesic action between any of these agents in clinical practice suggests that these factors tend to offset each other; clear evidence for weighting one factor over another is lacking. Hence, at the present state of knowledge, the Anaesthesia and Inlensil'e Care. Vol. 16 . No. 4. Nm 'ember, 1988 physicochemical properties of opioids do not suggest any unequivocal guide to either the ideal choice of opioid or of its incremental dose.
Receptor affinity of opioids: determinants of potency
Differences in drug potency are also determined by differences in the affinity of the various substances for the receptor(s). These values are usually determined by competitive displacement analysis. While fentanyl is approximately 200 times more potent than morphine in analgesic bioassays, its mu-receptor binding affinity in vitro is less than 10 times that of morphine. 14 Conversely, the potency of pethidine in various analgesic bioassays is between 10 and 25% that of morphine but its mu-receptor binding affinity is only approximately 2% that of morphine. 15 This is rationalised on the basis that the greater lipid solubility of fentanyl and pethidine allows them greater access to the receptors than morphine and that this tends to offset the apparent disparity between receptor affinity and potency.
Receptor dynamics also may regulate the time-course of drug action so that certain opioids, e.g. buprenorphine and lofentanil have durations of action that are more related to their rates of dissociation from receptors than their pharmacokinetics. 4 For the majority of the opioid agonist agents, however, the time-course of their effects can be explained by their pharmacokinetic characteristics, i.e. absorption from the site of administration, dilution of drug in the body and clearance of the drug from the body.
It should be added that some opioids may have a therapeutic (analgesic) ceiling and others can antagonise their own analgesic actions in animal laboratory tests (e.g. see Reference 16) . This would suggest that an opioid with agonist-antagonist characteristics would have little place in PCA. However, their use in PCA has been met with no more success or failure than the pure agonist opioids under the same circumstances. 17·20 Either selfantagonism does not occur within the dosage range required for postoperative analgesia or their actions on multiple opioid receptor systems 21 
-Hypothetical blood concentration curves from patient-controlled analgesia (PCA) illustrating a steady state in which drug dose input is matched by drug output. (a) The initial dilution volume V dilutes the dose D to a blood concentration increment Co, the total body clearance CL is equal to D divided by the area under the curve for that dosing interval and the total dilution volume Vss is equal to the product of CL and the mean residence time of drug in the body (MRT).
Global pharmacokinetic properties of opioids: a rationalisation of their relevance to peA It has become customary to determine the global kinetic parameters -distribution and clearance (from which half-life(s) become derived values) -by reference to the parameters of a compartmental model of the behaviour of the drug after intravenous administration. Note that the ratio ofVss/V -a major determinant of the 'distribution' phase -is important to the dissipation of effects after each demand. The ratio Vss/CL is the major determinant of the slow or 'elimination' half-life. The latter term is usually a misnomer; most opioid drugs can be eliminated at faster rates than the drugs can be washed out of tissue stores. may be rationalised, from first principles. First, the dose divided by the initial dilution volume (i.e. volume of the central compartment, V) equals the increment in blood drug concentration per dose. Thus V, for a drug with a small therapeutic index (see below), may determine the balance between therapeutic and adverse effects after each dose. If a loading dose is used to minimise the number of PC A 'demands' in the early period, it should be based on the product of desired blood drug concentration and V. Next, as time increases, the drug distributes to approach tissue: blood concentration equilibrium in a total dilution volume analogous to that which would pertain if the drug were infused to steady state conditions. Thus, the dose divided by the total dilution volume (Vss) gives the 'body' drug concentration (Figure 1 b) . The quotient, V ss/V determines the blood concentration decay rate after each incremental dose while the body comes to tissue: blood drug concentration equilibrium (Figure 1 b) . In PCA, both the incremental dose and the lockout interval between demanded doses should be considered on the basis of the resultant 'distribution' decay rate; the larger the value of Vss/V, the greater the relative distribution of drug dose to the 'total body' and the smaller the relative distribution to the receptors. Thus the incremental dose and the duration of effect are determined by Vss/V.
The magnitude of V depends markedly on the perfusion/functional volume relationship of all the structures providing the venous effluent being sampled; it thus always reflects the rate of drug washout from the lungs which comprise the first organ encountered after intravenous administration. It also reflects cardiovascular dynamics, the times at which samples are obtained, the sites of drug elimination and the linearity of all blood and tissue binding processes. In this sense, functional volume is the product of anatomical volume and drug tissue: blood partition coefficient. The other term, V ss, which can be determined without reference to any pharmacokinetic model, is a principal determinant of mean residence time of drug in the body; it is, however, influenced by the choice of blood sampling site in relation to drug elimination site. 22 When intravascular drug distribution between blood cells and plasma is not uniform, the magnitude of all pharmacokinetic model parameters may depend on whether drug concentrations in blood or plasma or serum are measured, as well as on the site chosen for blood sampling. 4 . 23 The lockout interval between doses should be related to the ratio of Vss/V which ~etermines the 'distribution' half-life of drug III blood. Because of vague characterisation, commonly reported values of 'distribution half-life' are generally so system-dependent as to be oflittle use for scientific inference. Yet it is plain that some drugs do distribute from blo,?d ~o ti.ssues faster than others and drug redlstnbutlOn occurs in some patients faster than others. It should be added that '(terminal) half-life' also needs to be viewed with considerable caution. The terminal half- With constant-rate drug administration, in order to maintain a constant mean effective drug blood concentration the mean infusion dose rate after loading will be determined solely by the mean total body clearance (CL). In PCA, the minimum demand rate would be expected to be equal to the product of CL and MEAC but, in practice, an average rate of 1.6-1.8 times this rate has been found to be required for adequate analgesia in a bolus demand system. 24 Alternatively, if a background infusion PCA system is to be used, a constant-rate infusion equal to the product of CL and MEAC could be supplemented by small incremental bolus doses to cope with patient demands for incident pain during this quasi-steady state. There is evidence that opioid blood drug concentration-response curves are steep,25 thus small changes in blood drug concentration can make the difference in a patient experiencing pain or being pain-free. In Figure 1 c, the hypothetical brain drug concentration profile is also shown. The rationale for the use of a concurrent background infusion is the avoidance of troughs in the brain drug concentration between bolus doses. A fixed-rate infusion however, appears to contribute little to th~ analgesic efficacy of on-demand analgesia. This, coupled with the natural time-course of pain and with variability in pharmacokinetics and in pain experience between patients provides the logic for a continuously variabl~ (adaptive) infusion. The logic for this method has been described 26 but has not yet reached clinical trial.
Experience with PCA has shown that the demand rates for opioid analgesics generally decrease with time, tending towards a plateau, consistent with the notion that patients at first take more frequent doses to 'load' the receptors and later less frequent doses for maintenance. An example, drawn from a recent study, is shown in Figure 2 . Several questions are pertinent. First, if the demand bolus dose is changed, does the demand rate change in accord so that the mean dose rate is preserved? The natural question that follows is, do patients make PCA demands at a consistent blood concentration? Hence, it also needs to be asked, is there an optimum dose for bolus demand? The answer to each question is only broadly yes! 400., Although there is an early decrease in mean demand-rate, the rate may not decrease uniformly, i.e. there are periods when discontinuities occur and periods when less frequent demands may be followed by periods of 'catch up , (Figure 3 ). There has been only limited investigation of the question of dose alteration; that patients do alter their rates in accord with the dose presented is shown in Figure 4 . This also shows that the patient made demands at slightly increasing plasma drug concentrations. Other evidence from a study of fentanyl over a longer period supports the position that patients do make demands at essentially consistent blood concentrations (a MEAC)27 that may decrease with time presumably as the pain stimulus decreases. There is contrary evidence that a substantial proportion of patients demand to an end-point other than the extinction of pain 28 and also that the size of the demanddose (increment) is a most important factor. 3 Clear evidence for an optimal dose is lacking. Various authorities have advocated the use of various doses of opioid analgesics --presumably based more on experience than scientific inference. 3 In the absence of data for the dose-dependent pharmacokinetics of morphine, such empirical data are best rationalised in terms of therapeutic index (see below) interpreted, in particular, as the maximum dose that produces appreciable analgesia without producing such immediately distressing side effects as disorientation, somnolence, nausea and vomiting. Other serious adverse-effects such as respiratory depression do not produce the same immediate distress to the patient. Recommendations for the intravenous demand-dose of morphine (for which there is most data) range from 1-4 mg 29 although smaller doses have been used. Preliminary data from a prospective comparison of 0.5, 1 and 2 mg morphine sulphate at the authors' institution suggest that doses of 1 mg are most appropriate.
It is important to remember that PCA is, invariably, a multiple dose system. The vast majority of pharmacokinetic studies of opioids have been performed only after single doses; limited data do not suggest that there are large differences.8.,o.3o.31.42 Moreover, most studies have been performed in volunteers rather than patients undergoing treatment of pain after surgery. How well such data relate to the milieu of PCA has not been tested extensively; limited data suggest that the differences could be appreciable. 32 . 33 Empirical PCA thus ought to succeed in treating pain more frequently than pharmacokinetically designed infusion regImens. Regional pharmacokinetics of opioids: a more rational basis for peA Some investigators have used so-called physiological modelling to account for the time-course of opioids in particular tissues. 34 This method is 'physiological' in that the various regions are assigned to receive drug in accordance with the regional distribution of cardiac output and the regional tissue: blood partition coefficients of the drug. It is assumed in this method that the regional equilibration of drug is limited only by perfusion -not by diffusion within the tissue. Recent studies from the authors' laboratory of drug uptake into and washout from tissues indicate that this assumption is not necessarily valid; diffusion may limit the rate of drug washout from tissues so that drug distribution into tissues may be indistinguishable from drug clearance. 35 In practice, the usefulness of physiological models to describe drug behaviour is limited by the amount of empirical data on which the models are based and on the difficulties in obtaining such data. 36
Receptor pharmacokinetics of opioids form a subset of the regional pharmacokinetics but can only be studied by 'effect compartment' methods in vivo.37.38.39 These are based on simultaneous analysis of the time courses of drug blood concentrations and drug effects. The parameters produced represent the equilibration time of drug between blood and compartment containing the receptors and the magnitude of the individual subject's sensitivity to the drug. Effect compartment modelling, therefore, allows useful comparisons to be made between drugs and between patients but the parameters are meaningful with reference only to the system from which they were derived. Using this methodology, faster CNS equilibration of alfentanil than fentanyl has been educed;37 the rate of equilibration then provides useful information for setting a lockout interval in PCA. 29 Drug delivery to anatomical regions containing receptors (e.g. brain) can be determined in vivo by the use of catheter techniques by which samples of blood entering and leaving the region in question can be obtained for drug analysis. Thus, if the actual regional blood flow can be estimated, the actual rates of drug influx and efflux, i.e. the net mass of drug per unit time passing between blood and tissue, to such regions can be measured directly: otherwise, the rates per unit blood flow can be determined. From these important parameters, the mass of substance in the region at any time (or mass per unit blood flow) can be determined. 40 However, such data are not readily available even for commonly used drugs. If such values were determined for opioid analgesics, not only could they be useful to compare and select the best drugs, but they may provide a set of parameters on which to decide between PCA variants and to set PCA variables.
The initial influx appears to be governed principally, if not solely, by the relative drug concentration gradient from blood to brain 29 which is virtually the same for all drugs after a single dose -thus, morphine is not particularly different from fentanyl. The efflux rate may depend on diffusion of the lipid soluble form of the drug and on the ratio of VssIV; thus, the rate of filling of other tissues influences the rate of change of brain concentrations. The mass of drug in the brain may depend on the lipid solubility of drug for facile passage out of the brain and/or on CL; thus, morphine may partition out slowly because of its relative hydrophilicity, methadone because of its low CL.1.4·6. 21 This rationale is consistent with other reported data from different experimental designs. Alfentanil is known to have exceedingly short time to onset of action but also a brief duration of action. 37 . 39 Fentanyl and pethidine are believed to have intermediate onset of action with durations that are limited more by redistribution of drug to other tissues than by elimination. 6.30.37 In reported experiments involving direct biopsy, morphine brain concentrations after bolus administration have been shown to be remarkably constant despite rapidly decreasing serum concentrations after bolus administration. 42 Because of the similarities in the rate of brain uptake between the drugs after bolus injection, the choice of drug, the bolus demand increment and maximum rate should be based more on the adverse effect profile and therapeutic index of the drug than on titration to particular blood concentrations. However, the marked differences in efflux rate between drugs suggests that in the context of PCA, the lockout interval should be based on the period of positive influx into brain (which would allow maximum appreciation of a dose before the next was allowed), rather than on inferences from conventional pharmacokinetics. These differences also suggest that it is extremely difficult to predecide dosing intervals and that PCA may be the optimal technique irrespective of the drug chosen because it does not require this decision.
Therapeutic index and therapeutic ratio: determinants of drug choice and dose
The concept of therapeutic index, i.e. the ratio of toxic to therapeutic doses (sometimes called the margin of safety), was introduced to express the relative safety of doses of drugs. With the advent of therapeutic drug monitoring, this has often been translated into the ratio of toxic to therapeutic blood concentrations or their difference expressed as a 'therapeutic window'. As applied to the administration of opioids for postoperative analgesia, values of therapeutic concentrations may be difficult to determine. It may not be possible to produce complete freedom from severe pain with partial agonists or agonist-antagonists; even with opioid agonists, toxic side effects may supervene before their full analgesic effect can be utilised. Values of toxic concentrations, likewise, may be difficult to determine because of the multiplicity of toxic effects encountered. Reported values of therapeutic index will have been obtained from wellspecified clinical or experimental conditions and refer to particular pharmacological effects (e.g. 43 ) and, although they appear to be fundamental properties of particular drugs, they are so only for the experimental conditions from which they were derived. Because it is life-threatening, respiratory depression is the most serious toxic effect of postoperative opioid analgesics but mental disorientation, somnolence, nausea and vomiting may be sufficiently troublesome in some patients to curtail the use of opioids. It is not at all certain whether these effects are more related to the absolute doses, absolute blood drug concentrations or the rate of change of blood drug concentrations. Thus, although quoted values of therapeutic index of opioids may appear to make one opioid analgesic more attractive than another, the fact that no drug has emerged as clearly outstanding suggests that it is unlikely that either laboratory determined values or current anecdotal reports offer much help in either drug choice or dose selection for postoperative analgesia. It would seem that respiratory depressant actions are associated with all of the opioid analgesics currently available, not just the pure mu-agonists,44-46 although it may reach a ceiling value within the clinical dose range of the agonistantagonist types. 47 -49 Whether future development of drugs or drug delivery strategies will allow clinical exploitation of the apparent opioid mu-receptor dualism to promote morphinoid analgesia without respiratory depression so remains to be seen.
Some conclusions
During the past decade, there has been a growing recognition that the treatment of pain has been less than optimal. This is despite the improvements of techniques for the administration of opioid drugs,2.s.6.2o.24 a variety of new opioids,sl the determination of the global pharmacokinetic characteristics of most opioids in clinical practice,4-6 and the generation of an enormous literature on opioid receptors and their endogenous agonists.14.1S.S2 A number of relevant issues have been identified as contributing to this situation; some of these have been enunciated previously.2.3 The development and introduction into clinical practice of peA, however, provides a method for the empirical drug treatment of pain which can bypass prublem issues related to inappropriate Anaesthesia and Intensil'e Care. Vol. /6. No. 4, No\'ember. /988 dosing regimens, unpredictable drug absorption and variations ill responses between patients.
If there are conclusions from the consideration of the science of PCA, they are related to the importance of selection of a suitable drug and of selection of PCA variables which allow titration of dose against effect with the least potential for adverse effects. It would seem that global pharmacokinetic characteristics are relatively unimportant in the context of PCA. Patient satisfaction is derived from a balance between efficacy and efficiency, i.e. the number of demands they have to make and the side effects experienced in achieving pain control. Thus, both pharmacokinetics and pharmacodynamics are involved but the weighting of the relevant components must be placed on the pharmacodynamics. The therapeutic index is the dominant characteristic but, as pointed out above, this is poorly characterised under clinical conditions.
If PCA is to be placed on a more scientific basis, a number of areas urgently require research; in particular, the regional and global pharmacokinetics need to be studied in relation to the size of demand, the duration of action of equi-efJective doses and why some patients obtain complete analgesia but others do not. With a knowledge of kinetics of drug delivery for particular body regions, it may be possible to control the rate of drug delivery from a PCA apparatus to optimise the uptake into brain or spinal cord while minimising the uptake into other regions. It is clear that the state of the science is in need of advancement in order to understand and design optimal techniques of drug administration in general, and PCA in particular.
